Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis

CONCLUSIONS: MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.PMID:38710474 | DOI:10.1016/j.aohep.2024.101511

Source: Annals of Hepatology - May 6, 2024 Category: Gastroenterology Authors: Luis Vega Daniela Simian Abraham I Gajardo Marcelo Salinas Andrea Urra M áximo Cattaneo Rosario Pino Juan P Roblero Álvaro Urzúa Katherine Rojas Jaime Poniachik Source Type: research